NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Ticker
$NVCR
Sector
Primary listing
Employees
1,605
Headquarters
Baar, Switzerland
Website
NovoCure Metrics
BasicAdvanced
$1.8bn
-
-$1.54
0.90
-
Price and volume
Market cap
$1.8bn
Beta
0.9
52-week high
$18.92
52-week low
$9.82
Average daily volume
1.7m
Financial strength
Current ratio
2.903
Quick ratio
2.658
Long term debt to equity
71.04
Total debt to equity
71.04
Interest coverage (TTM)
-9.18%
Profitability
EBITDA (TTM)
-163.915
Gross margin (TTM)
75.45%
Net profit margin (TTM)
-25.66%
Operating margin (TTM)
-26.37%
Effective tax rate (TTM)
1.24%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-11.06%
Return on equity (TTM)
-49.96%
Valuation
Price to revenue (TTM)
2.573
Price to book
5.4
Price to tangible book (TTM)
5.4
Price to free cash flow (TTM)
-36.09
Free cash flow yield (TTM)
-2.77%
Free cash flow per share (TTM)
-0.428
Growth
Revenue change (TTM)
8.48%
Earnings per share change (TTM)
1.79%
3-year revenue growth (CAGR)
8.88%
10-year revenue growth (CAGR)
32.34%
3-year earnings per share growth (CAGR)
4.67%
10-year earnings per share growth (CAGR)
-4.99%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs